DGX News and Press, Quest Diagnostics Incorporated From 08/21/23

2023-08-21 17:29:00 ET Baxter International ( NYSE: BAX ) said on Monday that it had appointed Stephen Rusckowski to its board of directors. According to BAX, Rusckowski is the former chairman, president, and chief executive officer of Quest Diagnostics ( ...

2023-08-15 02:37:34 ET Summary Quest Diagnostics has a strong Q2 with a slight beat on EPS and revenue. Quest’s base business appears to be recovering from the pandemic and pulled in $2.30B in revenue. Despite fading COVID-related revenue, Quest updated their full-year 2023...

2023-08-10 22:20:45 ET Summary Davis Selected Advisers' 13F portfolio increased by 8% to $16.41B in Q2 2023. The top three holdings in the portfolio are Meta Platforms, Berkshire Hathaway, and Wells Fargo. Stake increases were seen in Wells Fargo, Capital One Financial, Viatri...

2023-08-09 09:53:00 ET Alzheimer's patients could soon have more treatment options available. Biogen 's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli Lilly , donanemab, may not be far behind. The one drawba...

Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE PR Newswire Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of M...

Quest Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com PR Newswire AD-Detect ™ Test for Alzheimer's Disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognize...

2023-07-26 13:36:06 ET Quest Diagnostics, Inc. (DGX) Q2 2023 Earnings Conference Call July 26, 2023, 08:30 ET Company Participants Shawn Bevec - VP, IR James Davis - Chairman, CEO & President Sam Samad - EVP & CFO Conference Call Participants ...

2023-07-26 06:47:27 ET Quest Diagnostics press release ( NYSE: DGX ): Q2 Non-GAAP EPS of $2.30 beats by $0.04 . Revenue of $2.34B (-4.7% Y/Y) beats by $90M . Second quarter base business revenues of $2.30 billion, up 9.5% from 2022 Full year 2023 revenues n...

Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 PR Newswire Second quarter revenues of $2.34 billion , down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05 , up 4.6% from 2022; ...

2023-07-25 11:31:41 ET Quest Diagnostics ( NYSE: DGX ) is scheduled to announce Q2 earnings results on Wednesday, July 26th, before market open. The consensus EPS Estimate is $2.26 (-4.2% Y/Y) and the consensus Revenue Estimate is $2.25B (-8.2% Y/Y). Over the last 2 ye...